<DOC>
	<DOCNO>NCT00239408</DOCNO>
	<brief_summary>Evaluate whether effect inhale tiotropium bromide change trough forced expiratory volume ( FEV1 ) , compare placebo patient chronic obstructive pulmonary disease ( COPD ) , affect smoking status .</brief_summary>
	<brief_title>Spiriva ( Tiotropium Bromide ) Assessment FEV1 - ( SAFE-Portugal ) .</brief_title>
	<detailed_description>Evaluate whether effect inhale tiotropium bromide change trough FEV1 baseline week 12 compare placebo patient COPD affect smoke status . Secondary objective include FEV1 interim visit FVC on-treatment visit , use rescue medication , COPD symptom score , Physicians Global Evaluation EQ-5D score . Study Hypothesis : The primary objective study show superiority tiotropium placebo respect trough FEV1 12 week . Then 5 % two-sided hypothesis test : H0 : Mean trough FEV1 12 week tiotropium = Mean trough FEV1 12 week placebo H1 : Mean trough FEV1 12 week tiotropium unequal Mean trough FEV1 12 week placebo If null hypothesis reject favour alternative hypothesis ( H1 ) base patient , hypothesis test sub-populations current ex-smokers respectively . Comparison ( ) : Tiotropium bromide - 18 mcg capsule inhale via HandiHaler v Placebo powder capsule oral inhalation , via HandiHaler .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Main Inclusion criterion : 1.Diagnosis chronic obstructive pulmonary disease . 2.Patient male female , age &lt; =than 40 year . 3 . Patient smoke history &lt; =10 packyear.4.Patient able trained proper use HandiHaler 5.Patient able train perform technically satisfactory spirometry must able maintain record study period require protocol . 6.Patient must willing able sign inform consent prior participation study i.e . prior washout usual pulmonary medication . Main exclusion criterion 1.History asthma , allergic rhinitis atopy . 2 . A low respiratory tract infection COPD exacerbation past 4 week prior Visit 1 two week Screening Period 3.History life threaten bronchial obstruction , cystic fibrosis bronchiectasis 4 . Oral corticosteroid medication initiate modify within last 6 week prior Visit 1 daily dose &gt; 10 mg prednisone 20 mg every day ( equivalent ) . 5.Patients start stop exercise rehabilitation program within 4 week visit 6.Patients regularly use daytime oxygen therapy one hour per day , investigator 's opinion , unable abstain use oxygen therapy test . 7 . Patients undergone thoracotomy pulmonary resection lobectomy ( lung volume reduction surgery ) . 8.Tuberculosis indication treatment . 9 . Recent history ( i.e . 6 month less ) myocardial infarction.10 . Patients know moderate severe renal insufficiency.11 . Patients symptomatic prostatic hypertrophy bladder neck obstruction . 12.Patients know narrowangle glaucoma.13.History unstable arrhythmia life threaten event change therapy past year.14 . History cancer , treat basal cell carcinoma , within last 5 year 15.Intolerance anticholinergic contain product , and/or lactose component inhalation capsule delivery system.16.Patients treat betablockers include eye drops.17.Patients treat antihistamine ( H1 receptor antagonist ) , asthma exclude allergic condition ( See Exclusion Criteria No.2 ) .18.Patients treat monoamine oxidase inhibitor tricyclic antidepressants.19 . Patients treat oral betaadrenergics.20 . Patients take cromolyn sodium nedocromil sodium within 1 month Visit 1.21.Patients take antileukotrienes leukotriene receptor antagonist within 1 month Visit 1 . 22.Concomitant recent ( within last month 6 half life , whichever great ) use investigational drug prior screen visit ( Visit 1 ) . 23 . Significant alcohol drug abuse within past 12 month . 24 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception.24 . Previous participation study ( i.e . randomize ) .26 . Patients take commercially available Spiriva . 27.History clinically significant disease , define disease opinion investigator may patient risk participation study OR disease may influence result study OR patient 's ability participate study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>